The Food and Drug Administration approved the second over-the-counter naloxone nasal spray from the nonprofit, Harm Reduction Therapeutics, on Friday.
The move was welcomed as “a long time coming” by harm reduction workers in Allegheny County, making the medication available to anyone without a prescription.
Naloxone is a medication that can reverse an opioid overdose and is typically given via nasal spray or by intramuscular administration. Those on the ground working to prevent overdoses see it as a staple in the harm reduction tool kit. First responders in the region, including EMS, fire, and some police, carry the medication and use it frequently.
Opioid overdoses plague Allegheny County and the country. There were 108,000 overdose deaths in the U.S. in 2021, 66% of those involving the synthetic and incredibly deadly opioid, fentanyl.
Though overdose deaths decreased slightly — about 5% — in Allegheny County in 2022, more than 600 people in the county died from them, according to county health department data.
“We do not have a handle on [overdoses],” said Alice Bell, the overdose prevention program coordinator for syringe service and harm reduction organization, Prevention Point Pittsburgh. “Tons of people are dying from this all the time.”
Read More
“We know naloxone is a powerful tool to help quickly reverse the effects of opioids during an overdose,” said FDA Commissioner Robert Califf, in the release announcing the move.
“Ensuring naloxone is widely available, especially as an approved OTC product, makes a critical tool available to help protect public health. The agency has long prioritized access to naloxone products, and we welcome manufacturers of other naloxone products to discuss potential nonprescription development programs with the FDA.”
The product, called RiVive, will come as a 3-milligram nasal spray, compared to the 4-mg dose of the name-brand naloxone, Narcan, which was FDA-approved this past March.
Alice Bell said the adjustment of dose is a direct response to the harm reduction community’s request, as it’s common for people to administer too much naloxone instead of waiting the allotted 3 to 5 minutes for the drug to work. This can worsen the withdrawal symptoms of the medication after the person is revived.
The company that distributes Narcan has said it expects the product to hit the shelves in late September. Robert Ashford, executive director of nonclinical addiction support center, Unity Recovery, said RiVive fills a gap in care while people wait for Narcan to become more widely accessible.
“This is huge, because this approval for OTC is from a nonprofit … which is likely to result in significant price per unit reductions compared to [Narcan],” he said.
“It will continue to be the cheaper of the two options once both are readily available,” said Mr. Ashford. “Price matters for OTC meds.”
Ms. Bell agreed that Harm Reduction Therapeutics being a nonprofit organization is an added benefit to this news. “There’s no reason a naloxone nasal product needs to be as expensive as it is.”
Details about the rollout are still to come.
“We are grateful that FDA granted RiVive approval so we can now achieve what most thought impossible and no other company has: broad delivery of a lower-cost nasal naloxone product without a prescription to save lives that could otherwise be lost to opioid overdose,” said Michael Hufford in a company news release emailed to the Post-Gazette.
Mr. Hufford, co-founder and chief executive officer of Bethesda, Md.-based Harm Reduction Therapeutics and a Pennsylvania resident, praised the work of Prevention Point Pittsburgh in the release.
“Increasing access to this life-saving drug is an important step toward reducing the number of opioid overdoses and related deaths in our communities,” said Dr. Liz Cuevas, division chief of Allegheny Health Network’s Center for Inclusion Health. “It is encouraging to have yet another FDA-approved, over-the-counter naloxone product that stands to be more cost effective and widely available to those who need it.”
Both Ms. Bell and Mr. Ashford encouraged everyone to carry naloxone.
“It should be in every first aid kit, every purse, every car, every backpack,” said Mr. Ashford. “It’s easy to save a life and use naloxone. Everyone can do it. The biggest barrier is making sure people have it when they need it.”
Those interested in acquiring naloxone can visit a local pharmacy and inquire about their standing order of the medication, visit the site nextdistro.org and complete a brief training to get the medication for free, or visit Prevention Point Pittsburgh’s East Liberty location on Sundays.
Hanna Webster: hwebster@post-gazette.com





Comments
Welcome to Post-Gazette subscriber-only commenting community. Please review our community guidelines.